Consumers in the Middle East and Latin America who think they might be at risk of cardiovascular disease (CVD) will soon be able to access Bayer’s innovative Heart Risk Assessment Tool.
Bayer Wants Aspirin CVD Screening Tool To Reach 100m In US As It Plans International Roll-Out
Bayer hopes its innovative Aspirin-branded Heart Risk Assessment Tool will reach 100m in the US and its planning an international roll-out, the firm's general manager and vice president of pain and cardio, US, Kelly Fanning tells HBW Insight in an exclusive Q&A. Fanning also explains what Bayer is doing to manage the current surge in demand for Aspirin in the US, UK and Europe.
More from International
• By
Stada launches nine new Oilatum products in Saudi Arabia including “rich moisturising creams for intense hydration, gentle body washes for daily cleansing, and baby-specific products like soothing bath bubbles and head-to-toe wash.”
• By
Bayer Consumer Health, the Global Self-Care Federation and the Business Council for International Understanding outline in a paper how industry can work with multilateral organizations, governments, financial institutions, and stakeholders to "recognize and champion self-care as a fundamental driver of global health progress."
• By
PAGB CEO Michelle Riddalls and ISF president emeritus David Webber have been awarded OBEs for their services to consumer health and self-care.
• By
A round-up of the latest consumer health industry appointments: GSCF names next director general, MENAP-SCI elects chairman; Clasado hires BD director.
More from Geography
• By
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
• By
Maxwellia's “bold, honest, and completely unfiltered” campaign for Evana menstrual health brand tells the story of a woman dealing with the realities of a heavy period, showing “real blood, real leaks.”
• By
HBW Insight catches up with Maxwellia CEO Anna Maxwell to discuss her company's journey so far, and what she sees as the opportunities for Rx-to-OTC switch in UK women's health and beyond.